Vemurafenib (PLX4032)

For research use only.

Catalog No.S1267 Synonyms: RG7204, RO5185426

492 publications

Vemurafenib (PLX4032) Chemical Structure

CAS No. 918504-65-1

Vemurafenib (PLX4032, RG7204, RO5185426) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-RafV600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold. Vemurafenib (PLX4032, RG7204) induces autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 70 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Vemurafenib (PLX4032) has been cited by 492 publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Vemurafenib (PLX4032, RG7204, RO5185426) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-RafV600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold. Vemurafenib (PLX4032, RG7204) induces autophagy.
Features A novel and potent inhibitor of the B-RAFV600E oncoprotein.
Targets
SRMS [1]
(Cell-free assay)
ACK1 [1]
(Cell-free assay)
B-Raf (V600E) [1]
(Cell-free assay)
C-Raf [1]
(Cell-free assay)
MAP4K5 (KHS1) [1]
(Cell-free assay)
18 nM 19 nM 31 nM 48 nM 51 nM
In vitro

PLX4032 inhibits B-RAFV600E, C-RAF, as well as wildtype B-RAF, with IC50 of 31 nM, 48 nM and 100 nM, respectively. PLX4032 also inhibits several non-RAF kinases, including ACK1, KHS1, and SRMS, with IC50 of 18 nM to 51 nM. [1] In melanoma cell lines, the inhibitory effect by PLX4032 depends on B-RAF mutational status, because PLX4032 potently inhibits those harboring B-RAF V600 mutants, including V600E, V600D, V600K, and V600R, but not wildtype or other mutants. The IC50 values of PLX4032 on these cells, including MALME-3M, Colo829, Colo38, A375, SK-MEL28, and A2058, ranges from 20 nM to 1 μM. In these cells, PLX4032 (0.1 μM to 30 μM) also inhibits the phosphorylation of both MEK1/2 and ERK1/2. [2] PLX4032 is highly effective in the treatment of melanoma, for its ability of inhibiting B-RAFV600E. However, PLX4032 displays limited effect in colon cancer patients that also carrying B-RAFV600E oncoprotein. The reason for this is that, in colon cancer cells, B-RAFV600E inhibition by PLX4032 results in a rapid feedback EGFR activation, which compensates for the PLX4032-inhibited cell proliferation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL19 M2THcWZ2dmO2aX;uJGF{e2G7 NG\3VY43KM7:TR?= M3jJT|Q5KGh? MVjEUXNQ MkLxWJJq\2encoOgSXIhe3S{ZYPz NYPGR28{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOlIzPDBpPkKzN|YzOjRyPD;hQi=>
VMM12 MW\GeY5kfGmxbjDBd5NigQ>? MWOzJO69VQ>? M3nYO|Q5KGh? MlrjSG1UVw>? NVPuVXdoUW6lcnXhd4V{KGOxbHzh[4VvKHO7boTo[ZNqeyCjbnSg[IVkemWjc3XzJGlNNTliZYjwdoV{e2mxbh?= NWrqXFVsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5PFk2ODZpPkK1PVg6PTB4PD;hQi=>
C4 M3WxPWZ2dmO2aX;uJGF{e2G7 NUC0S5VlOyEQvF2= NFLPNGo1QCCq NEHHXI1FVVOR M2XUOWlv[3KnYYPld{Bkd2yuYXflckB{gW62aHXzbZMh[W6mIHTlZ5Jm[XOnczDJUE05KGW6cILld5Nqd25? M{Hh[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUi5OVA3Lz5{NUm4PVUxPjxxYU6=
Calu-6 NYHYOHlvTnWwY4Tpc44hSXO|YYm= MnryNgKBkc7:TR?= MV[xJIg> MV7EUXNQ NX7kXnJtSWO2aY\heIV{KE2HSz;FVmshcW5iY3XscJMhf2m2aDD3bYxlNXS7cHWgRnJCTg>? NW\xb3UyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxO|k4ODVpPkKwNVc6PzB3PD;hQi=>
PC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXW5OkBp Mn;aSWM2OD5iMUCwNEBvVQ>? NX7LWI1kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4PFA4QTJpPkG5PFgxPzl{PD;hQi=>
TPC-1 (RET/PTC1) NVziR41nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXqXmwxQTZiaB?= MkfaSWM2OOLLpUGwNFAhdk1? MlrWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OEC3PVIoRjF7OEiwO|kzRC:jPh?=
CAL62 (KRAS G12R) > 1000 > 1000 NXrCWW5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jCWlk3KGh? NETZe4dGSzVyPjCxNFAxKG6P M4jXUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEiwO|kzLz5zOUi4NFc6OjxxYU6=
HTH7 (NRAS Q61R) MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHKZmI6PiCq MnnSSWM2OOLLpTCxNFAxKG6P M4LENFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEiwO|kzLz5zOUi4NFc6OjxxYU6=
C643 (HRAS G13R)≥ 500 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H4U|k3KGh? MlrTSWM2OCEkibWgOVAxKG6P NX\5XnlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4PFA4QTJpPkG5PFgxPzl{PD;hQi=>
BCPAP (BRAF WT/V600E) M3;iTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnDPHE6PiCq NELtTWtGSzVyPUe4JI5O Mkm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OEC3PVIoRjF7OEiwO|kzRC:jPh?=
BHT101 (BRAF WT/V600E) Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHKepc6PiCq NU\ndYlHTUN3ME25O{BvVQ>? MnjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OEC3PVIoRjF7OEiwO|kzRC:jPh?=
SW1736 (BRAF WT/V600E) MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\tPVYhcA>? MnnzSWM2OD1{OTDuUS=> MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh6MEe5Nkc,OTl6OEC3PVI9N2F-
8505C (BRAF V600E/V600E) MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrkcZU6PiCq MlvNSWM2OD13NzDuUS=> MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh6MEe5Nkc,OTl6OEC3PVI9N2F-
ARO NGnGRVlHfW6ldHnvckBCe3OjeR?= MkTSNVAh|ryP NUTYXFRoPzJiaB?= NF7zR|VFVVOR MVjJcoR2[2W|IITo[UBz\WW6cILld5Nqd25ib3[geIhmKE6LUzDweY1x NUDubFlJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0OVgxPTNpPkG4OFU5ODV|PD;hQi=>
A375 NVXlTFFwSXCxcITvd4l{KEG|c3H5 MknBNVAh|ryP MXzEUXNQ M1z2OXBzd22xdHXzJIFxd3C2b4TpZ{Bl\WG2aB?= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR3OEC1N{c,OTh2NUiwOVM9N2F-
TPCI MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:4NVAxKM7:TR?= NIjzOHg6PiCq MUHEUXNQ MmLqTWM2OD1zMD63O{DPxE1? NWWwUFB5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0OVgxPTNpPkG4OFU5ODV|PD;hQi=>
ARO MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPYPYQyODBizszN MlTuPVYhcA>? M32zWGROW09? MoDaTWM2OD1{MEWgcm0> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR3OEC1N{c,OTh2NUiwOVM9N2F-
NPA MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjWZpYyODBizszN NEe0eFA6PiCq MkPMSG1UVw>? M3TyemlEPTB;Mk[gcm0> M2ey[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEW4NFU{Lz5zOES1PFA2OzxxYU6=
A375 NFPwTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCxNFAh|ryP NGPyW5E6PiCq M2X0OWROW09? Mn:1TWM2OD12NzDuUS=> NF7uSZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES1PFA2Oyd-MUi0OVgxPTN:L3G+
UKF-NB-3 (ABCB1) MoH6SpVv[3Srb36gRZN{[Xl? NX\0bZl7OS5{NTFCuW0> MkfENkBp NH7DZmlFVVOR NF2wRXNGdmijbnPld{Bi[2O3bYXsZZRqd25ib3[geIhmKG[udX;y[ZNk\W62IFHCR2IyKHO3YoP0doF1\SC{aH;kZY1qdmViMUKz NYC2eHdORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3N|U4PjZpPkK0O|M2PzZ4PD;hQi=>
UKF-NB-3 MX3GeY5kfGmxbjDBd5NigQ>? NIjJV3YyNjJ3INM1US=> MlTQNkBp NU\uPVZjTE2VTx?= Mn2wV4lodmmoaXPhcpRtgSCjZn\lZ5R{KG:wIHHjZ5VufWyjdHnvckBw\iC2aHWg[ox2d3Knc3PlcpQhSUKFQkGgd5Vje3S{YYTlJJJpd2SjbXnu[UAyOjN? M4PZUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{O1O|Y3Lz5{NEezOVc3PjxxYU6=
A375 (BRAFV600E) M2XHfWZ2dmO2aX;uJGF{e2G7 MmfRPEBp MkizSG1UVw>? NV\ZVnZ1UW6lcnXhd4V{KGmwdILhZ4VtdHWuYYKgVm9UKGGwZDDOU{Bt\X[nbIO= M4D5b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[zOlQ1Lz5{NUO2N|Y1PDxxYU6=
A375P M4rJRWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M1n3bmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUO3OXAh[2WubIOsJGlEPTBiPTCwMlI2PCEQvF2u NXjWS|l4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OlAxOzBpPkKyOFYxODNyPD;hQi=>
A375 Moe4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NHjUZWFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGzO|Uh[2WubIOg[ZhxemW|c3nu[{BDNVKjZjDWOlAxTSCvdYThcpQh[W6mIIfpcIQhfHmyZTDSZZMtKEmFNUCgQUAxNjNzIN88UU4> MlThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEi5NVEoRjJ{OEC4PVEyRC:jPh?=
A375P MlLSRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NYrTS|ZTPDhiaILz NGHROI5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGzO|VRKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCwMlI2KM7:TT6= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF{OESxNEc,OjRzMki0NVA9N2F-
A375 MW\DfZRwfG:6aXPpeJkh[XO|YYm= NGD0T3U4OiCqcoO= MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCwMlE5KM7:TT6= NHjnO5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKxOVgyQCd-MkSyNVU5OTh:L3G+
SK-MEL-28 MXXDfZRwfG:6aXPpeJkh[XO|YYm= NFexdm9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2PRVytNlgh[2WubIOg[ZhxemW|c3nu[{BDNXKjZjDWOlAxTSCvdYThcpQtKEmFNUCgQUAxNjFizszNMi=> MmPZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G0OlYoRjJ2NEexOFY3RC:jPh?=
M229 M1znT2N6fG:2b4jpZ4l1gSCjc4PhfS=> NWnRSZRYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVTJ{OTDj[YxteyCneIDy[ZN{cW6pIFKtdoFnKFZ4MEDFJI12fGGwdDygTWM2OCB;IECuNUDPxE1w Mn33QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G0OlYoRjJ2NEexOFY3RC:jPh?=
M263 Ml\NR5l1d3SxeHnjbZR6KGG|c3H5 NV\C[o5XS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVTJ4MzDj[YxteyCneIDy[ZN{cW6pIFKtdoFnKFZ4MEDFJI12fGGwdDygTWM2OCB;IECuNUDPxE1w MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5MUS2Okc,OjR2N{G0OlY9N2F-
M321 MoHzR5l1d3SxeHnjbZR6KGG|c3H5 M2\UcWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG0{OjFiY3XscJMh\XiycnXzd4lv\yCELYLh[kBXPjByRTDteZRidnRuIFnDOVAhRSByLkGg{txONg>? NWjrbnU6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O|E1PjZpPkK0OFcyPDZ4PD;hQi=>
M238 NULHOppNS3m2b4TvfIlkcXS7IHHzd4F6 MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNNlM5KGOnbHzzJIV5eHKnc4PpcochSi2{YX[gWlYxOEVibYX0ZY51NCCLQ{WwJF0hOC5zIN88UU4> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5MUS2Okc,OjR2N{G0OlY9N2F-
M262 NUfHSWt6S3m2b4TvfIlkcXS7IHHzd4F6 MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNNlYzKGOnbHzzJIV5eHKnc4PpcochSi2{YX[gWlYxOEVibYX0ZY51NCCLQ{WwJF0hOC5zIN88UU4> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5MUS2Okc,OjR2N{G0OlY9N2F-
M249 M4\vS2N6fG:2b4jpZ4l1gSCjc4PhfS=> M3vVeGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG0zPDliY3XscJMh\XiycnXzd4lv\yCELYLh[kBXPjByRTDteZRidnRuIFnDOVAhRSByLkGg{txONg>? MkP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G0OlYoRjJ2NEexOFY3RC:jPh?=
M14 MlvJR5l1d3SxeHnjbZR6KGG|c3H5 M4roPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG0yPCClZXzsd{BmgHC{ZYPzbY5oKE6UQWOgS|EzSyCvdYThcpQtKEmFNUCgQUAxNjF3IN88UU4> M1SwTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEexOFY3Lz5{NES3NVQ3PjxxYU6=
SK-MEL-28 M3izcWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NEHsS403QCCqcoO= NVTSbohjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1OTUxvMkigZ4VtdHNiaHHyZo9zcW6pIFLSRWYhXjZyMFWgcZV1[W62IHHmeIVzKDZ6IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkS4JO69VS5? NUG1W4xGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFgxPzNpPkK0OVg5ODd|PD;hQi=>
insect cell M134V2Z2dmO2aX;uJIF{e2G7 MXO2NEBucW6| NELjSplKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJIh2dWGwIFKtVoFnKFZ4MEDFJI12fGGwdDDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiaX7z[YN1KGOnbHzzJIF{e2W|c3XkJIF{KFupYX3tZU0{O1CfaX7jc5Jxd3KjdHnvckBqdnSxIF3FT{Bi\nSncjC2NEBucW6|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVAhRSByLkCzNUDPxE1w NH\xdI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFMyPSd-MkS5NFA{OTV:L3G+
MALME-3M M3TwZ2Z2dmO2aX;uJIF{e2G7 M13pd|EhcHJ? MVHJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfC2vZXTpZZRm\CCHcnugdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIF3BUG1GNTOPIHPlcIx{KGGodHXyJFEhcHJiYomg[ox2d3Knc3PlcoNmKGGwYXz5d4l{NCCLQ{WwJF0hOC5yNkGg{txONg>? MmqxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECzNVUoRjJ2OUCwN|E2RC:jPh?=
A375 M1HORWZ2dmO2aX;uJIF{e2G7 M3v4d|EhcHJ? NEDP[XdKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdD3t[YRq[XSnZDDFdosheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGE{PzViY3XscJMh[W[2ZYKgNUBpeiCkeTDmcJVwemW|Y3XuZ4Uh[W6jbInzbZMtKEmFNUCgQUAxNjF7IN88UU4> M{\hS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwN|E2Lz5{NEmwNFMyPTxxYU6=
COLO205 MkXwR5l1d3SxeHnjbZR6KGG|c3H5 NX61flNGPCCmYYnz NVTJZ29NS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0:OT{KwOUBk\WyuczDh[pRmeiB2IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygSWM2OCB;IECuNlQh|ryPLh?= MlewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECzNVUoRjJ2OUCwN|E2RC:jPh?=
WM266.4 NIfB[|ZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NImwRmQ1QCCqcoO= MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFePMk[2MlQh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFYh|ryPLh?= M3\EPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[3NFA3Lz5{NUK2O|AxPjxxYU6=
A375 M2r4OmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NV7HfXg3PDhiaILz M33wRmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUO3OUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMD6xPUDPxE1w NFX5fWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2O|AxPid-MkWyOlcxODZ:L3G+
WM1361 M13UU2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 M37KUlQ5KGi{cx?= M2XxdGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iV12xN|YyKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCxMlg4KM7:TT6= M1TXblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[3NFA3Lz5{NUK2O|AxPjxxYU6=
A375 M1nlS2Z2dmO2aX;uJIF{e2G7 MX\Jcohq[mm2aX;uJI9nKEJvcnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCDM{e1JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCHUluxM|IheGixc4Doc5J6dGG2aX;uJIlv[3WkYYTl[EBnd3JiOUCgcYlveyCkeTDX[ZN1\XKwIHLsc5R1cW6pIH3leIhw\CxiSVO1NEA:KDBwMEOzNUDPxE1w M1PqS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[yNlY4Lz5{NUS2NlI3PzxxYU6=
A375 Mm\wRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M4H4SVczKGi{cx?= MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF|N{WgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOFS{igZZN{[XluIFnDOVAhRSB|LkOxOUDPxE1w MmXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkKyOlcoRjJ3NE[yNlY4RC:jPh?=
SK-MEL-2 MX\GeY5kfGmxbjDhd5NigQ>? Mk\CTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViQj3yZYYhcW5iaIXtZY4hW0tvTVXMMVIh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIFXST|EwOiCyaH;zdIhwenmuYYTpc44hcW6ldXLheIVlKG[xcjC5NEBucW6|IHL5JHdme3Sncn6gZoxwfHSrbnegcYV1cG:m M1HoWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[yNlY4Lz5{NUS2NlI3PzxxYU6=
A375 MmjuSpVv[3Srb36gZZN{[Xl? NXflTXBCPzJiaILz MXrJcohq[mm2aX;uJI9nKEKUQV[gWlYxOEVibYX0ZY51KGmwIHj1cYFvKEF|N{WgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCHUlugdIhwe3Cqb4L5cIF1cW:wIH3lZZN2emWmIHHmeIVzKDd{IHjyd{BjgSCHTFnTRUBie3OjeTygTWM2OCB;IECuNVUh|ryPLh?= MkTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkW4NFQoRjJ3OU[1PFA1RC:jPh?=
A375 Ml3vRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M4HlWFczKGi{cx?= NYHtR3U3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDy[ZNignW{aX6gZZN{[XluIFnDOVAhRSByLkG3JO69VS5? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4NUiwOEc,OjV7NkW4NFQ9N2F-
A375 NH7yfZhHfW6ldHnvckBie3OjeR?= NUnNWJBnOTVibXnudy=> MofKR49ueGW2aYTpeoUh[mmwZHnu[{Bi\m[rbnn0fUB1dyCEUlHGJIlvKGi3bXHuJGE{PzViY3XscJMh[W[2ZYKgNVUhdWmwczDpckBxemW|ZX7j[UBw\iCDVGCgZY5idG:pdXWsJGlEPTBiPTCwMlI3KM7:TT6= Mn72QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkW4NFQoRjJ3OU[1PFA1RC:jPh?=
A375 NXXxOGRXTnWwY4Tpc44h[XO|YYm= M3rUWVE2KG2rboO= Mn6zR49ueGW2aYTpeoUh[mmwZHnu[{Bi\m[rbnn0fUB1dyCDUlHGJIlvKGi3bXHuJGE{PzViY3XscJMh[W[2ZYKgNVUhdWmwczDpckBxemW|ZX7j[UBw\iCDVGCgZY5idG:pdXWsJGlEPTBiPTCwMlk2KM7:TT6= NW\vVphERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlU5ODRpPkK1PVY2QDB2PD;hQi=>
HCT116 MlzJSpVv[3Srb36gZZN{[Xl? NHf3WXpKdmirYnn0bY9vKG:oIFvSRXMhTzF|RDDteZRidnRiaX6gbJVu[W5iSFPUNVE3KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gSXJMKHCqb4PwbI9zgWyjdHnvckBjgSCHTFnTRUwhUUN3MDC9JFE3NjZizszNMi=> NUDCNmE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlU5ODRpPkK1PVY2QDB2PD;hQi=>
HCT116 Mmr6SpVv[3Srb36gZZN{[Xl? NFrzOZkxNjN2IITvJFIxODByIH7N NGTkb|BR[XKjZH;4bYNidCCjY4TpeoF1cW:wIH;mJHJCWy:UQV[vUWVMKHOrZ37hcIlv\yCyYYToe4F6KGmwIHj1cYFvKEiFVEGxOkBk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBDWkGIIHHzd4V{e2WmIHHzJGVTUyCyaH;zdIhwenmuYYTpc44h[XRiMD6zOEB1dyB{MECwNEBvVQ>? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4NUiwOEc,OjV7NkW4NFQ9N2F-
NZM20 MmHGRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MWO2PEBpenN? M3jxNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTmrNNlAh[2WubIOg[ZhxemW|c3nu[{BDNVKjZjDWOlAxTSCvdYThcpQhcXOxbHH0[YQh\nKxbTDO[ZchYmWjbHHu[EBu\XSjc4TheIlkKG2nbHHuc41iKHCjdHnlcpQhcW6ldXLheIVlKG[xcjC2PEBpenNiYomgV3JDKGG|c3H5MEBKSzVyIE2gNE4xOjRizszNMi=> MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByNUWzNEc,OjZyMEW1N|A9N2F-
NZM07 NGmzNFlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MVm2PEBpenN? NYLrVGNxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOXm0xPyClZXzsd{BmgHC{ZYPzbY5oKEJvUnHmJHY3ODCHIH31eIFvfCCrc3;sZZRm\CCocn;tJG5mfyCcZXHsZY5lKG2ndHHzeIF1cWNibXXsZY5wdWFicHH0bYVvfCCrbnP1ZoF1\WRiZn;yJFY5KGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjB|NjFOwG0v Ml\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMEW1N|AoRjJ4MEC1OVMxRC:jPh?=
A375 MnfMRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NFrH[2s3QCCqcoO= M4X5XWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUO3OUBk\WyuczDlfJBz\XO|aX7nJGIuWmGoIG[2NFBGKG23dHHueEBqdmO3YnH0[YQh\m:{IE[4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCwMlA4QSEQvF2u MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByNUWzNEc,OjZyMEW1N|A9N2F-
COLO205 MkHpRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M1;F[|Y5KGi{cx?= NHXNcXBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPPUG8zODViY3XscJMh\XiycnXzd4lv\yCELWLh[kBXPjByRTDteZRidnRiaX7jeYJifGWmIH\vdkA3QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5|MEmg{txONg>? NF32cpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwOVU{OCd-Mk[wNFU2OzB:L3G+
SK-MEL-28 MlOyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MWi2PEBpenN? NF:yR4JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMW1GVC1{ODDj[YxteyCneIDy[ZN{cW6pIFKtVoFnKFZ4MEDFJI12fGGwdDDpcoN2[mG2ZXSg[o9zKDZ6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkO4NUDPxE1w MoXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMEW1N|AoRjJ4MEC1OVMxRC:jPh?=
HT-29 MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NVHT[XJSPjhiaILz M1HWfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGStNlkh[2WubIOg[ZhxemW|c3nu[{BDNVKjZjDWOlAxTSCvdYThcpQhcW6ldXLheIVlKG[xcjC2PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE43ODFizszNMi=> NH;kZ|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwOVU{OCd-Mk[wNFU2OzB:L3G+
SK-MEL-1 NFzhc3hCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MWi2PEBpenN? MoXWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVSz3NSWwuOSClZXzsd{BmgHC{ZYPzbY5oKEJvUnHmJHY3ODCHIH31eIFvfCCrbnP1ZoF1\WRiZn;yJFY5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAyNjR7OTFOwG0v NU\6N5lFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFU2OzBpPkK2NFA2PTNyPD;hQi=>
NZM40 MY\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NV\obZVGPjhiaILz NYr5bFhZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOXm01OCClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCELWLh[kBqe2:uYYTl[EBnem:vIF7le{Bb\WGuYX7kJI1mfGG|dHH0bYMhdWWuYX7vcYEheGG2aXXueEBqdmO3YnH0[YQh\m:{IE[4JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTBiPTCzMlAyKM7:TT6= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByNUWzNEc,OjZyMEW1N|A9N2F-
NZM09 NYX6UIZNSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NXjKVoIyPjhiaILz NHTFXFdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7aUVA6KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEJvUnHmJIl{d2yjdHXkJIZzd21iTnX3JHpm[WyjbnSgcYV1[XO2YYTpZ{Bu\Wyjbn;tZUBx[XSrZX70JIlv[3WkYYTl[EBnd3JiNkigbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IEiuN|Mh|ryPLh?= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByNUWzNEc,OjZyMEW1N|A9N2F-
A375P MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M{jadFczKGi{cx?= NUj2ZoFqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN|c2WCClZXzsd{BmgHC{ZYPzbY5oKEKUQV[gWlYxOEVibYX0ZY51KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCLQ{WwJF0hOC5|NzFOwG0v NF33fpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkeyOFc{OCd-Mk[3NlQ4OzB:L3G+
BL21(DE3) NHGyTZJHfW6ldHnvckBie3OjeR?= M3z0VmlvcGmkaYTpc44hd2ZiTj30[ZJucW6jbDDobZMufGGpZ3XkJGJTSUZiVk[wNGUhdXW2YX70JEg1PDhidH:gO|I{KHKnc3nkeYV{MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEpTEV|KTDj[YxteyCjc4Pld5Nm\CCjczDwbI9{eGixconsZZRqd25ib3[gZolwfGmweXzheIVlNU2HSzDifUBCdHCqYWPjdoVmdiCjc4PhfUwhUUN3MDC9JFAvODNzIN88UU4> MmL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6NUK2NlMoRjJ4OEWyOlI{RC:jPh?=
A375 MmLGSpVv[3Srb36gZZN{[Xl? NWfkXY8yOSCqch?= Mn;UTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRiaX6gbJVu[W5iQUO3OUBk\WyuczDhd5Nme3OnZDDhd{BGWkticHjvd5Bpd3K7bHH0bY9vKHC{ZXnuZ5Vj[XSnZDDmc5IhOSCqcjDifUBY\XO2ZYLuJIJtd3RibXX0bI9lNCCLQ{WwJF0hOC5yMUeg{txONg>? MmXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyOEW2O|IoRjJ5MEi1OlczRC:jPh?=
MIAPaCa2 MX\GeY5kfGmxbjDhd5NigQ>? MXmxJIhz MlXFTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViQj3SZYYhcW5iaIXtZY4hVUmDUHHDZVIh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIFXST{BxcG:|cHjvdplt[XSrb36gdJJmcW6ldXLheIVlKG[xcjCxJIhzKGK7IGfld5Rmem5iYnzveEBu\XSqb3SsJGVEPTBiPTCyMlI6KM7:TT6= NXnOe2x7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewPFU3PzJpPkK3NFg2Pjd{PD;hQi=>
COLO205 NUfBeWk5S3m2b4TvfIlkcXS7IHHzd4F6 M4DId|czKGi{cx?= M4XsTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNQVE9{MEWgZ4VtdHNiaHHyZo9zcW6pIFKtVoFnKFZ4MEDFJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4xPDRizszNMi=> M3HkZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUW1PFk6Lz5{N{G1OVg6QTxxYU6=
HT-29 MW\DfZRwfG:6aXPpeJkh[XO|YYm= M2PIb|czKGi{cx?= MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bp[XKkb4LpcochSi2UYX[gWlYxOEVibYX0ZY51KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkG1OkDPxE1w NX;E[nVsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexOVU5QTlpPkK3NVU2QDl7PD;hQi=>
HCT116 Ml3hR5l1d3SxeHnjbZR6KGG|c3H5 MV23NkBpenN? M4XkcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCqYYLic5Jqdmdid3ns[EB1gXCnIFKtVoFnKGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzND61PEDPxE1w MoTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzNUW4PVkoRjJ5MUW1PFk6RC:jPh?=
WM266.4 Ml60RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NX[xb5d5OjRiaILz MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFePMk[2MlQh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IECuNlEh|ryPLh?= MoP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd{M{i4OFEoRjJ5MkO4PFQyRC:jPh?=
WM266.4 MnLDRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MorLNlQhcHK| M2LFT2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iV12yOlYvPCClZXzsd{Bp[XKkb4LpcochSlKDRjDWOlAxTSCvdYThcpQh[XO|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjCyOEBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4xPyEQvF2u MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzZ|NEG5OUc,Ojd4M{SxPVU9N2F-
A375 MV3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NITaVHkzPCCqcoO= M1LCcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUO3OUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkKxJO69VS5? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzZ|NEG5OUc,Ojd4M{SxPVU9N2F-
WM1361 MX;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MUOyOEBpenN? MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFePMUO2NUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzLki2JO69VS5? NE\6TWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[zOFE6PSd-Mke2N|QyQTV:L3G+
SK-MEL-28 NV;FPGw5SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NXHWZZJDPDhiaILz M3SxfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUWVNNTJ6IHPlcIx{KGijcnLvdolv\yCEUlHGJHY3ODCHIH31eIFvfCCjc4Pld5Nm\CCjczDjc45k\W62cnH0bY9vKHKncYXpdoVlKG[xcjD0c5RidCCpcn;3eIghcW6qaXLpeIlwdiCvZXHzeZJm\CCjZoTldkA1QCCqcoOgdoV{[Xq3cnnuJIF{e2G7LDDUS2khRSB{IN88UU4> M3HLdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVM4Lz5{N{e3OFE{PzxxYU6=
SK-MEL-28 MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXyxJIhz M3znZWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2yPEBk\WyuczDoZZJjd3KrbnegRnJCTiCYNkCwSUBufXSjboSgdJJmcW6ldXLheIVlKG[xcjCxJIhzKG[xbHzve4VlKGK7IHnydoFlcWG2aX;uJI9nKDFwMUOgb3cwdTJiVW[tcIlocHRiZn;yJFUhdWmwczDt[YF{fXKnZDDh[pRmeiB2ODDodpMhemW|YYr1dolvKGG|c3H5 M2HpVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVM4Lz5{N{e3OFE{PzxxYU6=
A375 NWTUSnB3SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M1nGVlczKGi{cx?= MmPhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbJVu[W5iQUO3OUBk\WyuczDh[pRmeiB5MjDodpMh[nliY3XscEB1cXSncj3ncI8hdHWvaX7ld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC55IN88UU4> MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ2MkW1N{c,Ojh{NEK1OVM9N2F-
COLO205 NGXkOIdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MmSxO|IhcHK| Ml20RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbJVu[W5iQ1;MU|IxPSClZXzsd{Bi\nSncjC3NkBpenNiYomgZ4VtdCC2aYTldk1odG9ibIXtbY5me2OnbnPlJIF{e2G7LDDJR|UxKD1iNT6xOkDPxE1w NXn6cpdiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyOFI2PTNpPkK4NlQzPTV|PD;hQi=>
HepG2 M{jxc2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 MXG3NkBpenN? M1G0NWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIh2dWGwIFjldGczKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDj[YxtKHSrdHXyMYdtdyCudX3pcoV{[2WwY3WgZZN{[XluIFnDOVAhRSB3LkS4JO69VS5? MoXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{NEK1OVMoRjJ6MkSyOVU{RC:jPh?=
SK-MEL-2 MVPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NGrGWIc4OiCqcoO= NVzWUVlJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcHWvYX6gV2suVUWOLUKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHygeIl1\XJvZ3zvJIx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFUvPjRizszNMi=> M{LoNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkSyOVU{Lz5{OEK0NlU2OzxxYU6=
K562 M3jMdmZ2dmO2aX;uJIF{e2G7 MYSxJIhz NX7vWWduW3SjYnnsbZpifGmxbjDv[kBDWkGIIHnuJIh2dWGwIFu1OlIh[2WubIOgZYZ1\XJiMTDodkBjgSC2aHXycYFtKHOqaX\0JIF{e2G7LDDFR|UxKD1iMD63PVQ{OyEQvF2u NVfpNINCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFAzPjFpPkK4NlgxOjZzPD;hQi=>
K562 MXTGeY5kfGmxbjDhd5NigQ>? NEXWOFMyKGi{ MorDV5Ri[mmuaYrheIlwdiCxZjDGSWNJKGmwIHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhOSCqcjDifUB1cGW{bXHsJJNpcW[2IHHzd4F6NCCHQ{WwJF0hPS5yMUG4O{DPxE1w NV;XcpNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFAzPjFpPkK4NlgxOjZzPD;hQi=>
A375M M1jUcGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MYO3NkBpenN? NVv5SGFESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN|c2VSClZXzsd{Bp[XKkb4LpcochSlKDRjDWOlAxTSCvdYThcpQh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvPSEQvF2u NWf3VJUzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OVgyOzRpPkK4OFU5OTN2PD;hQi=>
1205 Lu NYP6Z2FpSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NWfjSo5EPzJiaILz M3TjNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iMUKwOUBNfSClZXzsd{Bp[XKkb4LpcochSlKDRjDWOlAxTSCvdYThcpQh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFIh|ryPLh?= NV3JRplnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OVgyOzRpPkK4OFU5OTN2PD;hQi=>
A375M MlLaRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MV60PEBpenN? NUjtPHR[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN|c2VSClZXzsd{Bp[XKkb4LpcochSlKDRjDWOlAxTSCvdYThcpQh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFIvODVizszNMi=> NULWb2c6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OVgyOzRpPkK4OFU5OTN2PD;hQi=>
UACC-903 M2fmUmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MmDPO|IhcHK| M1vBV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVVHDR{06ODNiY3XscJMhcGG{Yn;ybY5oKEKUQV[gWlYxOEVibYX0ZY51KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAzNjdizszNMi=> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR3OEGzOEc,Ojh2NUixN|Q9N2F-
1205 Lu Mnz2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NV7hcWVYPDhiaILz Mly1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiBzMkC1JGx2KGOnbHzzJIhiemKxcnnu[{BDWkGIIG[2NFBGKG23dHHueEBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gO{43KM7:TT6= NEDXWFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES1PFE{PCd-Mki0OVgyOzR:L3G+
UACC-903 NWDNOXhbSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MYS0PEBpenN? MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFWDQ1OtPVA{KGOnbHzzJIhiemKxcnnu[{BDWkGIIG[2NFBGKG23dHHueEBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNVIvOyEQvF2u MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR3OEGzOEc,Ojh2NUixN|Q9N2F-
CHL-1 NX\tXZQ6SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NFqwTmY4OiCqcoO= NUflfHVGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDTGwuOSClZXzsd{Bp[XKkb4Lpcochf2muZDD0fZBmKEKUQV[gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGyMlch|ryPLh?= NX;wfG5vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OVgyOzRpPkK4OFU5OTN2PD;hQi=>
CHL-1 NHXDWppCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MX:0PEBpenN? Mlz5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFSFytNUBk\WyuczDoZZJjd3Krbnege4lt\CC2eYDlJGJTSUZiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJyIN88UU4> NH;Jc3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES1PFE{PCd-Mki0OVgyOzR:L3G+
HCT116 MkLISpVv[3Srb36gZZN{[Xl? NXj3SVNjW3SrbYXsZZRqd25ib3[gRnJCTi2FUlHGJIRqdWW{aYrheIlwdiCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZpkhdHWlaX\ldoF{\SClb33wcIVu\W62YYTpc44h[XO|YYmsJGVEPTBiPTCwMlYxOSEQvF2u M{LEUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUW3OFU5Lz5{OEW1O|Q2QDxxYU6=
Calu6 MnjZSpVv[3Srb36gZZN{[Xl? NH;sd4Y{KHWP Mk\6NkBpenN? M{HaWWFkfGm4YYTpc44hd2ZiQ2LBSkBqdiCqdX3hckBE[Wy3NjDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBOTUticHjvd5Bpd3K7bHH0bY9vKGG2IEOgeW0h[W[2ZYKgNkBpenNiYomgSnJGXCCjc4PhfS=> NFvQVHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O|Q2QCd-Mki1OVc1PTh:L3G+
Sf9 Mm\1SpVv[3Srb36gZZN{[Xl? NV3uVFE5OSCqch?= Ml3lTY5pcWKrdHnvckBw\iCqdX3hckBbSUtiKEWgeI8hOzB7IILld4llfWW|KTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[5JIlve2WldDDj[YxteyC3c3nu[{BbSUu2aXTlJIF{KHO3YoP0doF1\SCjZoTldkAyKGi{IHL5JI1ie3Nic4DlZ5Rzd22ndIL5MEBKSzVyIE2gNE4xOjNizszNMi=> MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV6NkKxNUc,Ojh3OE[yNVE9N2F-
Sf9 NV:0dHhvTnWwY4Tpc44h[XO|YYm= M4j4PFMxKG2rboO= NX\PVZpmUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGdUXC22YXfn[YQhemWlb33ibY5idnRiaIXtZY4h\nWubD3s[Y5ofGhiWlHLJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDT[lkhcW6|ZXP0JINmdGy|IIXzbY5oKE2EUDDhd{B{fWK|dILheIUh[W[2ZYKgN|AhdWmwczDifUBCTFBvR3zvJIF{e2G7LDDJR|UxKD1iMD6wN|E1KM7:TT6= M1exSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUi2NlEyLz5{OEW4OlIyOTxxYU6=
UACC-903 MV\DfZRwfG:6aXPpeJkh[XO|YYm= MlrBNlUhfU1? MYK0PEBpenN? NGDTNYZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWSUOFLUmwN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDheEAzPSC3TTDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7IILlcIF1cX[nIITvJINwdnS{b3ysJGlEPTBiPTCzMlYh|ryPLh?= NVXhSVVxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxN|MxOzVpPkK5NVM{ODN3PD;hQi=>
CHL-1 NFGyNHlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NIXpUm44OiCqcoO= MmH5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFSFytNUBk\WyuczDoZZJjd3Krbnege4lt\CC2eYDlJGJTSUZiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDF|Lkeg{txONg>? M4nYZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUOzNFM2Lz5{OUGzN|A{PTxxYU6=
A375 MUfGeY5kfGmxbjDhd5NigQ>? M3HzbVk3KGi{cx?= MlO1TY5pcWKrdHnvckBw\iCEUlHGJHY3ODCHIH31eIFvfCCrbjDoeY1idiCDM{e1JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJBzd2yrZnXyZZRqd25iaX7jeYJifGWmIH\vdkA6PiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5zMkeg{txONg>? MnOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5O|coRjJ7NEC3PVc4RC:jPh?=
A375 NYHU[XpFTnWwY4Tpc44h[XO|YYm= Mn7pTY5pcWKrdHnvckBw\iCEUlHGJHY3ODCHIH31eIFvfCCrbjDoeY1idiCDM{e1JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCHUlugdIhwe3Cqb4L5cIF1cW:wIHL5JGFteGijU3Py[YVvKGG|c3H5MEBKSzVyIE2gNE4xOzJizszNMi=> NFjveog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2NVgzPyd-Mkm0OlE5Ojd:L3G+
SK-MEL-32 NY\pPGdLS3m2b4TvfIlkcXS7IHHzd4F6 NX6w[lBQS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0tvTVXMMVMzKGOnbHzzMEBKSzVyIE2gNE4{OSEQvF2u M4PJU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[xPFI4Lz5{OUS2NVgzPzxxYU6=
WM266.4 NIfT[oVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MmrwOFghcHK| MkLuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCZTUK2Ok41KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGdKPTBiPTCwMlIyKM7:TT6= MlHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7NEC0OlMoRjJ7OUSwOFY{RC:jPh?=
A375 NXnBfoxwSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MmjBOFghcHK| NHvSbpFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGzO|Uh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IECuPVUh|ryPLh?= MonnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7NEC0OlMoRjJ7OUSwOFY{RC:jPh?=
HT-29 NVG2OnBuSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M{LJ[lQ5KGi{cx?= MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSBzLki4JO69VS5? NVfkPJVpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5OFA1PjNpPkK5PVQxPDZ|PD;hQi=>
WM1361 M1GxfmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MXG0PEBpenN? MljORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCZTUGzOlEh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IEKwMlgh|ryPLh?= NIO0[ZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUm0NFQ3Oyd-Mkm5OFA1PjN:L3G+
HCT116 NIrhWGpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NF7td3c1QCCqcoO= NFXlZoJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBIUTVyIE2gNlUvOiEQvF2u Mme4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7NEC0OlMoRjJ7OUSwOFY{RC:jPh?=
A673 MXrxTHRUKGG|c3H5 MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? MmPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
DAOY NVjGbnI2eUiWUzDhd5NigQ>? MV3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? NXrrXolFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD MlvFdWhVWyCjc4PhfS=> MWjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> M{faSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH MkO2dWhVWyCjc4PhfS=> NFy4XlhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=> NXP6[4VuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R) M1PRTZFJXFNiYYPzZZk> MmTHdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| M3LjflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 MkfTdWhVWyCjc4PhfS=> NUG4ZWdMeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> NV2zV|dKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 M3HJV5FJXFNiYYPzZZk> NG\rSWlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz Mn\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 NYD2bFFYeUiWUzDhd5NigQ>? M{TnWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq M4X1TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS M3LMNZFJXFNiYYPzZZk> NGr0WXdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN? M4mwb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 NGHYdmhyUFSVIHHzd4F6 M3:zeZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJM> NHv0OWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 NFLCUGRyUFSVIHHzd4F6 NFjWUFVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> M2PXXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC MlfMdWhVWyCjc4PhfS=> NVjnWXZveUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 MnHZdWhVWyCjc4PhfS=> NHfwWWpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MVTxTHRUKGG|c3H5 MkPxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TC32 MlT4dWhVWyCjc4PhfS=> NFK1UGhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{ MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / p-CRAF; 

PubMed: 22448344     


BRAF mutant cell lines from (A) were treated with 3µM vemurafenib for the indicated times, and lysates were probed with the indicated antibodies.

p-MEK(S217/221) / pAKT(T308) / p-AKT(S473) / p-P70 S6K(T389) / p-S6(Ser235-236) / P-4EB-P1; 

PubMed: 22194965     


Western blot analysis of phosphorylated and the total amount of key proteins in the MAPK and PI3K/AKT pathways after 24 hours of exposure to the solvent (DMSO), or various concentrations of the BRAF inhibitor vemurafenib. The vemurafenib-sensitive M238 and M229 cell lines and the vemurafenib in vitro acquired resistant sublines M238-AR2 and M229-AR9 were cultured at different concentrations of vemurafenib. p70 and p-p70 S6K in this figure are referred to S6K1 and phosphorylated form of S6K1, respectively.

Bax / Bcl2 / Bcl-xl / BIM / Mcl1; 

PubMed: 28382170     


Change of Bcl-2 family proteins following Vemurafenib treatment for 24 h.

22448344 22194965 28382170
Growth inhibition assay
Cell viability; 

PubMed: 29179510     


At different time point of the experiment (expressed in days), sensitivity to vemurafenib was evaluated in the different A375 cell lines. Cells were treated with 10-fold dilution series (1 nM to 10 uM) of Vemurafenib and cell viability was assessed after 72 h by Crystal violet staining. Cell viability results are expressed in fold vs. the untreated cells.

29179510
Immunofluorescence
uPAR / α5-β1; 

PubMed: 30611716     


Representative images of confocal microscopy of companion M6R treated cultures stained with specific anti-uPAR (red), α5β1 (green) and DAPI (blue). Experiments have been performed three times in triplicate with analogous results. The co-localization score is quantified by image J andreported within each picture as Manders' coefficient (MC). The shown pictures are representative of 20 different pictures for each experimental condition. Scale bar = 20 μm.

p-Akt(Thr308); 

PubMed: 27293997     


Vemurafenib reduced phosphorylated Akt in HUVEC. Cells were treated with vemurafenib for 4 h and processed for immunofluorescence staining with antibodies against p-AktThr308. Cell nuclei were stained with DAPI. Scale bar represents 50 μm. 

30611716 27293997
In vivo In B-RAFV600E-mutant mice xenograft models, PLX4032 (6 mg/kg–20 mg/kg) inhibits tumor growth. [1] In mice xenograft models of LOX, Colo829, and A375 cells, PLX4032 (12.5 mg/kg–100 mg/kg) inhibits tumor growth and prolongs mice survival. [2]

Protocol

Kinase Assay:

[1]

- Collapse

RAF kinase activity measurements:

The kinase activities of wild-type RAF and mutants are determined by measuring phosphorylation of biotinylated-BAD protein. For each enzyme (0.01 ng), 20 μL reactions are carried out in 20 mM Hepes (pH 7.0), 10 mM MgCl2, 1 mM DTT, 0.01% (v/v) Tween-20, 50 nM biotin-BAD protein, and 1 mM ATP at room temperature. Reactions are stopped at 5 min with 5 μL of a solution containing 20 mM Hepes (pH 7.0), 200 mM NaCl, 80 mM EDTA, 0.3% (w/v) bovine serum albumin (BSA). The stop solution also includes phospho-BAD (Ser112) antibody, streptavidin-coated donor beads, and protein A acceptor beads. The antibody and beads are pre-incubated in stop solution in the dark at room temperature for 30 min. The final dilution of antibody is 1/2000 and the final concentration of each bead is 10 μg/mL. The assay plates are incubated at room temperature for one hour and then are read on a PerkinElmer AlphaQuest reader. Mutant activities are the average of two different batches of purified protein assayed in duplicate in three different experiments.
Cell Research:

[2]

- Collapse
  • Cell lines: MALME-3M, Colo829, Colo38, A375, SK-MEL28, and A2058 cells
  • Concentrations: 0–10 μM , dissolved in DMSO
  • Incubation Time: 5 days
  • Method:

    Cellular proliferation is evaluated by MTT assay. Briefly, cells are plated in 96-well microtiter plates at a density of 1000 to 5000 cells per well in a volume of 180 μL. PLX4032 is prepared at 10 times the final assay concentration in media containing 1% DMSO. Twenty-four hours after cell plating, 20 μL of the appropriate dilution of PLX4032 are added to plates in duplicate. The plates are assayed for proliferation 6 days after the cells are plated. Percent inhibition is calculated and the IC50 is determined from the regression of a plot of the logarithm of the concentration versus percent inhibition.


    (Only for Reference)
Animal Research:

[2]

- Collapse
  • Animal Models: Mice (athymic nude) xenograft models of LOX, Colo829, and A375 cells
  • Dosages: 12.5 mg/kg–100 mg/kg
  • Administration: Oral gavage twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 97 mg/mL (197.99 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+61% ddH2O
For best results, use promptly after mixing.
1.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 489.92
Formula

C23H18ClF2N3O3S

CAS No. 918504-65-1
Storage powder
in solvent
Synonyms RG7204, RO5185426
Smiles CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03013491 Active not recruiting Drug: CX-072|Drug: ipilimumab|Drug: vemurafenib Solid Tumor|Lymphoma CytomX Therapeutics January 2017 Phase 1|Phase 2
NCT02441465 Completed Drug: Vemurafenib|Drug: 14C-Labeled Vemurafenib Malignant Melanoma Cancer Hoffmann-La Roche August 13 2015 Phase 1
NCT02427893 Withdrawn Drug: Cobimetinib|Drug: Vemurafenib Melanoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Genentech Inc. August 2015 Phase 3
NCT02036086 Active not recruiting Drug: Vemurafenib|Drug: Cobimetinib Melanoma Sunnybrook Health Sciences Centre August 2015 Phase 2
NCT02456701 Completed Biological: KTN3379|Drug: vemurafenib Thyroid Cancer Celldex Therapeutics|Memorial Sloan Kettering Cancer Center June 2015 Phase 1
NCT02304809 Active not recruiting Drug: Vemurafenib Solid Tumors|Hematologic Cancers|Metastatic Cancers UNICANCER|National Cancer Institute France|Fondation ARC|Hoffmann-La Roche October 13 2014 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How about the half-life of Vemurafenib(S1267)?

  • Answer:

    It was reported that the half-life of the compound is 57 hours.

  • Question 2:

    The vemurafenib power, when prepared in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O solutions, form a pellet down the tube?

  • Answer:

    When prepare this kind of vehicle, please dissolve the drug in DMSO clearly first. If it dissolves not readily, please sonicate and warm in the water bath at about 45 degree. Then add PEG and Tween. After they mixed homogeneously, then dilute with water.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products

Tags: buy Vemurafenib (PLX4032) | Vemurafenib (PLX4032) supplier | purchase Vemurafenib (PLX4032) | Vemurafenib (PLX4032) cost | Vemurafenib (PLX4032) manufacturer | order Vemurafenib (PLX4032) | Vemurafenib (PLX4032) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID